Skip to main content

Advertisement

SpringerLink
Log in

Pharmaceutical application and development of fixed-dose combination: dosage form review

  • Review
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

Background

Fixed dose combination (FDC) products are common in the treatment of various disease such as hypertension, diabetes, HIV and HCV, Pain, Respiratory disease for improving therapeutic efficacy and tolerability. They make it possible to combine more than two drug molecules with optimal doses, dosage form and optimize the treatment.

Area covered

This review provides discussions of the FDC application in variety of disease. various formulation technologies such as bilayer system, active film coating, co-crystal, multi-particulate system, Hot-melt co-extrusion, hot fusion method, spray drying and 3D-printing that consider characteristics of each active pharmaceutical ingredient (API) in FDC to maximize the benefits and overcome the challenges of developing FDC products.

Expert opinion

FDC has utilized as a promising dosage form to increase the oral absorption of drugs. From beneficial perspective, they offer efficacy and safety improvement, product exclusivity, patient compliance, medicinal cost reduction. while disadvantage perspectives such as a lack of dose flexibility, drug interaction, difference dosage regimen, dose difference and difference of physicochemical properties should be considered for the use of FDC, differences in individual drug characteristics, drug release profiles, therapeutic dose, and solubility should be considered for FDCs design and formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Abdelquader MM, Essa EA, El Maghraby GM (2019) Inhibition of co-crystallization of olmesartan medoxomil and hydrochlorothiazide for enhanced dissolution rate in their fixed dose combination. AAPS PharmSciTech 20:3

    Article  CAS  Google Scholar 

  • Abdul S, Poddar S (2004) A flexible technology for modified release of drugs: multi layered tablets. J Control Release 97:393–405

    Article  CAS  PubMed  Google Scholar 

  • Abebe A, Akseli I, Sprockel O, Kottala N, Cuitiño AM (2014) Review of bilayer tablet technology. Int J Pharm 461:549–558

    Article  CAS  PubMed  Google Scholar 

  • Akseli I, Dey D, Cetinkaya C (2010) Mechanical property characterization of bilayered tablets using nondestructive air-coupled acoustics. AAPS PharmSciTech 11:90–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Albanna AS, Smith BM, Cowan D, Menzies D (2013) Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 42:721–732

    Article  CAS  PubMed  Google Scholar 

  • Andrews G, Li S, Almajaan A, Yu T, Martini L, Healy A, Jones D (2019) Fixed dose combination formulations: multilayered platforms designed for the management of cardiovascular disease. Mol Pharm 16:1827–1838

    Article  CAS  PubMed  Google Scholar 

  • Arnfast L, Kamruzzaman M, Löbmann K, Aho J, Baldursdottir S et al (2017) Melt extrusion of high-dose co-amorphous drug-drug combinations. Pharm Res 34:2689–2697

    Article  CAS  PubMed  Google Scholar 

  • Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S et al (2013) Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity 21:2163–2171

    Article  CAS  PubMed  Google Scholar 

  • Aryal S, Škalko-Basnet N (2008) Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer types. Acta Pharm 58:299–308

    Article  CAS  PubMed  Google Scholar 

  • Association AD (2018) 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 41:S73

    Article  Google Scholar 

  • Awad A, Fina F, Trenfield SJ, Patel P, Goyanes A, Gaisford S, Basit AW (2019) 3D printed pellets (miniprintlets): a novel, multi-drug, controlled release platform technology. Pharmaceutics 11:148

    Article  CAS  PubMed Central  Google Scholar 

  • Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–719

    Article  PubMed  Google Scholar 

  • Battini S, Mannava MC, Nangia A (2018) Improved stability of tuberculosis drug fixed-dose combination using isoniazid-caffeic acid and vanillic acid cocrystal. J Pharm Sci 107:1667–1679

    Article  CAS  PubMed  Google Scholar 

  • Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM et al (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154:602–613

    Article  PubMed  PubMed Central  Google Scholar 

  • Bhutani H, Singh S, Jindal K, Chakraborti AK (2005) Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J Pharm Biomed Anal 39:892–899

    Article  CAS  PubMed  Google Scholar 

  • Bjerrum OJ, Gautam Y, Honoré PH, Vana V (2014) Drug–drug combinations revisited. Eur J Hosp Pharm Sci Pract 21:8–12

    Article  Google Scholar 

  • Borghi C, Cicero AF (2010) Rationale for the use of a fixed-dose combination in the management of hypertension. Clin Drug Investig 30:843–854

    Article  CAS  PubMed  Google Scholar 

  • Bourlière M, Pietri O (2019) Hepatitis C virus therapy: no one will be left behind. Int J Antimicrob Agents 53:755–760

    Article  PubMed  CAS  Google Scholar 

  • Brock D, Zeitler J, Funke A, Knop K, Kleinebudde P (2012) A comparison of quality control methods for active coating processes. Int J Pharm 439:289–295

    Article  CAS  PubMed  Google Scholar 

  • Brun J, Jones R (2001) Nonsteroidal anti-inflammatory drug–associated dyspepsia: the scale of the problem. Am J Med 110:S12–S13

    Article  Google Scholar 

  • Burke MD, He X, Cook C, Petrov GA, Long S, Coffin MD (2013) Stability enhancement of drug layered pellets in a fixed dose combination tablet. AAPS PharmSciTech 14:312–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Caldwell WB, Kaushal AM (2017) Multiparticulate drug delivery. Springer, Berlin

    Google Scholar 

  • Cameron F, Whiteside G, Mckeage K (2012) Phentermine and topiramate extended release (QsymiaTM). Drugs 72:2033–2042

    Article  CAS  PubMed  Google Scholar 

  • Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A et al (2014) A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 64:2071–2082

    Article  PubMed  Google Scholar 

  • Chaudhary M, Shrivastava SM, Sehgal R (2009) Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections. Curr Clin Pharmacol 4:62–66

    Article  CAS  PubMed  Google Scholar 

  • Chen W, Wang J, Desai D, Chang SY, Kiang S et al (2017) A strategy for tablet active film coating formulation development using a content uniformity model and quality by design principles. Compr Qual Design Pharm Prod Devel Manuf, 193–233

  • Clarke A & Doughty D (2017) Development of liquid dispensing technology for the manufacture of low dose drug products. Cont Manuf Pharm, 551–575

  • Coleman JJ, Schuster CR, Dupont RL (2010) Reducing the abuse potential of controlled substances. Pharm Med 24:21–36

    Article  Google Scholar 

  • Coyne CP, Narayanan L (2019) Anti-neoplastic cytotoxicity by complementary simultaneous selective targeted delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C 21-phosphoramidate)-[anti-EGFR]. J Pharm Investig 49:173–193

    Article  CAS  Google Scholar 

  • Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB et al (2007) Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm 33:909–926

    Article  CAS  PubMed  Google Scholar 

  • De La Sierra A, Roca-Cusachs A, Redon J, Marin R, Luque M et al (2009) Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients. Clin Drug Investig 29:459–469

    Article  PubMed  Google Scholar 

  • Delea TE, Stanford RH, Hagiwara M, Stempel DA (2008) Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin 24:3435–3442

    Article  CAS  PubMed  Google Scholar 

  • Demiri V, Stranzinger S, Rinner P, Piller M, Sacher S et al (2018) Gluing pills technology: a novel route to multilayer tablet manufacturing. Int J Pharm 548:672–681

    Article  CAS  PubMed  Google Scholar 

  • Den Hollander JG, Horrevorts AM, Van Goor M, Verbrugh HA, Mouton JW (1997) Synergism between tobramycin and ceftazidime against a resistant pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 41:95–100

    Article  Google Scholar 

  • Dengale SJ, Grohganz H, Rades T, Löbmann K (2016) Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev 100:116–125

    Article  CAS  PubMed  Google Scholar 

  • Desai D, Rao V, Guo H, Li D, Stein D et al (2012) An active film-coating approach to enhance chemical stability of a potent drug molecule. Pharm Dev Technol 17:227–235

    Article  CAS  PubMed  Google Scholar 

  • Desai D, Wang J, Wen H, Li X, Timmins P (2013) Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol 18:1265–1276

    Article  CAS  PubMed  Google Scholar 

  • Dey N, Majumdar S, Rao M (2008) Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 7:1067–1075

    Article  Google Scholar 

  • Dey S, Chattopadhyay S, Mazumder B (2014) Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. BioMed Res Inter 2014:396106

    Article  CAS  Google Scholar 

  • Dhiman N, Awasthi R, Jindal S, Khatri S, Dua K (2016) Development of bilayer tablets with modified release of selected incompatible drugs. Polim Med 46:5–15

    Article  PubMed  Google Scholar 

  • Dierickx L, Remon JP, Vervaet C (2013) Co-extrusion as manufacturing technique for multilayer mini-matrices with dual drug release. Eur J Pharm Biopharm 85:1157–1163

    Article  CAS  PubMed  Google Scholar 

  • Duggirala NK, PerryZaworotko MLMJ (2016) Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun 52:640–655

    Article  CAS  Google Scholar 

  • Efentakis M, Peponaki C (2008) Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on carbopols with isosorbite mononitrate. AAPS PharmSciTech 9:917–923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • EMaCFMPFHU (2009) Guideline on clinical development of fixed combination medicinal products.

  • El Hagrasy AS, Chang S-Y, Desai D, Kiang S (2006) Raman spectroscopy for the determination of coating uniformity of tablets: assessment of product quality and coating pan mixing efficiency during scale-up. J Pharm Innov 1:37–42

    Article  Google Scholar 

  • El Kafrawy N, Rashwan M, Lion K, Khedr K, Nashaat N (2014) Effectiveness and tolerability of fixed dose combination of amlodipine/valsartan in treatment of hypertension in the real-life setting among Egyptian patients. Egypt Heart J 66:30–35

    Article  Google Scholar 

  • Erdine S (2010) Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens 12:40–46

    Article  CAS  Google Scholar 

  • Fernández-García R, Prada M, Bolás-Fernández F, Ballesteros MP, Serrano DR (2020) Oral fixed-dose combination pharmaceutical products: industrial manufacturing versus personalized 3D printing. Pharm Res 37:1–22

    Article  CAS  Google Scholar 

  • Food and Drug Administration (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm070241.pdf

  • Food and Drug Administration (2006) Fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV

  • Food and Drug Administration (2014) Guidance for industry: new chemical entity exclusivity determinations for certain fixed-combination drug products. US Department of Health and Human Services, Rockville, Maryland

    Google Scholar 

  • Food and Drug Administration (2018) Hypertension: developing fixed-dose combination drug products for treatment guidance for industry. Hypertension developing fixed-dose combination drug products for treatment guidance for industry

  • Fule R, Dhamecha D, Maniruzzaman M, Khale A, Amin P (2015) Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): evaluating amorphous state and in vivo performance. Int J Pharm 496:137–156

    Article  CAS  PubMed  Google Scholar 

  • Furlanetto S, Cirri M, Maestrelli F, Corti G, Mura P (2006) Study of formulation variables influencing the drug release rate from matrix tablets by experimental design. Eur J Pharm Biopharm 62:77–84

    Article  CAS  PubMed  Google Scholar 

  • Gandhi R, Kaul CL, Panchagnula R (1999) Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today 2:160–170

    Article  CAS  Google Scholar 

  • Gao JZ, Jain A, Motheram R, Gray D, Hussain M (2002) Fluid bed granulation of a poorly water soluble, low density, micronized drug: comparison with high shear granulation. Int J Pharm 237:1–14

    Article  CAS  PubMed  Google Scholar 

  • Gautam Y, Bjerrum OJ, Schmiegelow M (2015) The wider use of fixed-dose combinations emphasizes the need for a global approach to regulatory guideline development. Ther Innov Regul Sci 49:197–204

    Article  PubMed  Google Scholar 

  • Gendre C, Boiret M, Genty M, Chaminade P, Pean JM (2011) Real-time predictions of drug release and end point detection of a coating operation by in-line near infrared measurements. Int J Pharm 421:237–243

    Article  CAS  PubMed  Google Scholar 

  • Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987

    Article  CAS  PubMed  Google Scholar 

  • Hao J, Rodriguez-Monguio R, Seoane-Vazquez E (2015) Fixed-dose combination drug approvals, patents and market exclusivities compared to single active ingredient pharmaceuticals. PLoS ONE 10:e0140708

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Haring AP, Tong Y, Halper J, Johnson BN (2018) Programming of multicomponent temporal release profiles in 3D printed polypills via core–shell, multilayer, and gradient concentration profiles. Adv Healthcare Mater 7:1800213

    Article  CAS  Google Scholar 

  • Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M (2011) Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 27:1243–1253

    Article  CAS  PubMed  Google Scholar 

  • Hurst JR, Gruffydd-Jones K, Biswas M, Guranlioglu D, Jenkins M et al (2020) Efficacy and safety of LAMA/LABA fixed-dose combination therapies in chronic obstructive pulmonary disease: a systematic review of direct and indirect treatment comparisons. Int J Chron Obstruct Pulmon Dis 15:1529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huynh DTN, Jin Y, Heo K-S (2019) Therapeutic targets and drugs for hyper-proliferation of vascular smooth muscle cells. J Pharm Investig 50:337–347

    Article  CAS  Google Scholar 

  • Joshi SR, Ramachandran A, Chadha M, Chatterjee S, Rathod R et al (2014) Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. Expert Opin Pharmacother 15:1611–1620

    Article  CAS  PubMed  Google Scholar 

  • Just S, Toschkoff G, Funke A, Djuric D, Scharrer G et al (2013) Optimization of the inter-tablet coating uniformity for an active coating process at lab and pilot scale. Int J Pharm 457:1–8

    Article  CAS  PubMed  Google Scholar 

  • Kelleher J, Gilvary G, Madi A, Jones D, Li S et al (2018) A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination products. Int J Pharm 545:183–196

    Article  CAS  PubMed  Google Scholar 

  • Kerns EH (2001) High throughput physicochemical profiling for drug discovery. J Pharm Sci 90:1838–1858

    Article  CAS  PubMed  Google Scholar 

  • Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ (2015) 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J Control Release 217:308–314

    Article  CAS  PubMed  Google Scholar 

  • Kim J-Y, Kim D-W, Kuk Y-M, Park C-W, Rhee Y-S et al (2012) Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes. Int J Pharm 427:201–208

    Article  CAS  PubMed  Google Scholar 

  • Kwon KC, Lee C (2017) Analysis of fixed-dose combination products approved by the us food and drug administration, 2010–2015: implications for designing a regulatory shortcut to new drug application. Ther Innov Regul Sci 51:111–117

    Article  PubMed  Google Scholar 

  • Lakshman JP, Kowalski J, Vasanthavada M, Tong WQ, Joshi YM et al (2011) Application of melt granulation technology to enhance tabletting properties of poorly compactible high-dose drugs. J Pharm Sci 100:1553–1565

    Article  CAS  PubMed  Google Scholar 

  • Laukamp EJ, Vynckier A-K, Voorspoels J, Thommes M, Breitkreutz J (2015) Development of sustained and dual drug release co-extrusion formulations for individual dosing. Eur J Pharm Biopharm 89:357–364

    Article  CAS  PubMed  Google Scholar 

  • Liu F, Song Y, Liu Y-N, Li Y-T, Wu Z-Y et al (2018) Drug-bridge-drug ternary cocrystallization strategy for antituberculosis drugs combination. Cryst Growth Des 18:1283–1286

    Article  CAS  Google Scholar 

  • Lung T, Jan S, De Silva HA, Guggilla R, Maulik PK et al (2019) Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. Lancet Glob Health 7:e1359–e1366

    Article  PubMed  Google Scholar 

  • Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R et al (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536

    PubMed  Google Scholar 

  • Mandal U, Pal TK (2008) Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm 34:305–313

    Article  CAS  PubMed  Google Scholar 

  • Martin K, Abebe A, Raghavan K, Stamato H, Timmins P (2012) In: AAPS Annual Conference.

  • Marzolini C, Gibbons S, Khoo S, Back D (2016) Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother 71:1755–1758

    Article  CAS  PubMed  Google Scholar 

  • Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E (2002) Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 24:460–467

    Article  PubMed  Google Scholar 

  • Milan-Segovia R, Dominguez-Ramirez A, Jung-Cook H, Magana-Aquino M, Romero-Mendez M et al (2010) Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis 14:1454–1460

    CAS  PubMed  Google Scholar 

  • Ministry of Food and Drug Safety (2018) Clinical guideline for fixed-dose combination (Complainant's Guide)

  • Mitra A, Wu Y (2012) Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J 14:646–655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mohammed G, Puri V, Bansal AK (2008) Coprocessing of nevirapine and stavudine by spray drying. Pharm Dev Technol 13:299–310

    Article  CAS  PubMed  Google Scholar 

  • Moriarty F, Bennett K, Fahey T (2019) Fixed-dose combination antihypertensives and risk of medication errors. Heart 105:204–209

    Article  CAS  PubMed  Google Scholar 

  • Moulding T, Le H, Rikleen D, Davidson P (2004) Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 8:743–748

    CAS  PubMed  Google Scholar 

  • Nikghalb LA, Singh G, Singh G, Kahkeshan KF (2012) Solid dispersion: methods and polymers to increase the solubility of poorly soluble drugs. J Appl Pharm Sci 2:170–175

    Google Scholar 

  • Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S et al (2008) Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull 56:1455–1458

    Article  CAS  Google Scholar 

  • Okafor NI, Nkanga CI, Walker RB, Noundou XS, Krause RWM (2020) Encapsulation and physicochemical evaluation of efavirenz in liposomes. J Pharm Investig 50:201–208

    Article  CAS  Google Scholar 

  • Pagliotto ADF, Caleffi-Ferracioli KR, Lopes MA, Baldin VP, Leite CQF et al (2016) Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination. J Microbiol Immunol Infect 49:980–983

    Article  CAS  PubMed  Google Scholar 

  • Pan F, Chernew ME, Fendrick AM (2008) Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 23:611–614

    Article  PubMed  PubMed Central  Google Scholar 

  • Park CK, Kwon YS (2014) Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease. Tuberc Respir Dis 77:161–166

    Article  Google Scholar 

  • Park BJ, Choi HJ, Moon SJ, Kim SJ, Bajracharya R et al (2019) Pharmaceutical applications of 3D printing technology: current understanding and future perspectives. J Pharm Investig 49:575–585

    Google Scholar 

  • Park H-S, Lee D-H, Han J-H, Jung S-H, Lee M et al (2020) The effects of combined treatment of losartan and ramipril on hypertension and related complications. J Pharm Investig 50:573–581

    Article  CAS  Google Scholar 

  • Patel J, Shah A, Sheth N (2009) Aqueous-based film coating of tablets: study the effect of critical process parameters. Int J Pharm Tech Res 1:235–240

    CAS  Google Scholar 

  • Patil H, Tiwari RV, Repka MA (2016) Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech 17:20–42

    Article  CAS  PubMed  Google Scholar 

  • Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM et al (2007) Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm 336:22–34

    Article  CAS  PubMed  Google Scholar 

  • Pergolizzi JV Jr, Van De Laar M, Langford R, Mellinghoff H-U, Merchante IM et al (2012) Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. J Pain Res 5:327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Persons AGSPOTPMOPPIO (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57:1331–1346

    Article  Google Scholar 

  • PMRMD Forms (2002) With eudragit polymers. Pharma Polymers 9(2):3

    Google Scholar 

  • Pourkavoos N (2012) Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. Comb Prod Ther 2:2

    Article  Google Scholar 

  • Qiu Y, Zhang G, Wise D (2000) Research and development aspects of oral controlled-release dosage forms, handbook of pharmaceutical controlled release technology. Marcel Dekker Inc, NewYork

    Google Scholar 

  • Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD et al (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1· 25 million people. The Lancet 383:1899–1911

    Article  Google Scholar 

  • Rathbone MJ, Hadgraft J, Roberts MS (2002) Modified-release drug delivery technology. CRC Press, Florida

    Book  Google Scholar 

  • Riekes MK, Engelen A, Appeltans B, Rombaut P, Stulzer HK et al (2016) New perspectives for fixed dose combinations of poorly water-soluble compounds: a case study with ezetimibe and lovastatin. Pharm Res 33:1259–1275

    Article  CAS  PubMed  Google Scholar 

  • Riekes MK, Dereymaker A, Berben P, Augustijns P, Stulzer HK et al (2017) Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: investigation of formulation and process parameters. Int J Pharm 520:49–58

    Article  CAS  PubMed  Google Scholar 

  • Roche N, Plaza V, Backer V, Van Der Palen J, Cerveri I et al (2020) Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study). NPJ Primary Care Respiratory Medicine 30:1–7

    Article  PubMed  PubMed Central  Google Scholar 

  • Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E et al (2018) LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis 13:3115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sadia M, Isreb A, Abbadi I, Isreb M, Aziz D et al (2018) From fixed dose combinations to a dynamic dose combiner: 3D printed bi-layer antihypertensive tablets. Eur J Pharm Sci 123:484–494

    Article  CAS  PubMed  Google Scholar 

  • Sandberg A, Ragnarsson G, Jonsson U, Sjögren J (1988) Design of a new multiple-unit controlled-release formulation of metoprolol—metoprolol CR. Eur J Clin Pharmacol 33:S3–S7

    Article  CAS  PubMed  Google Scholar 

  • Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ (2012) Amorphous-state characterization of efavirenz—polymer hot-melt extrusion systems for dissolution enhancement. J Pharm Sci 101:3456–3464

    Article  CAS  PubMed  Google Scholar 

  • Scheiman JM (2013) The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 15:S5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Scheinberg M, Júnior HP, De Almeida ME, De Oliveira MFB, Ecclissato C et al (2018) Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Drug Des Dev Ther 12:2775

    Article  CAS  Google Scholar 

  • Serrano DR, Walsh D, O’connell P, Mugheirbi NA, Worku ZA et al (2018) Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating. Eur J Pharm Biopharm 124:13–27

    Article  CAS  PubMed  Google Scholar 

  • Shah N, Mehta T, Gohel M (2017) Formulation and optimization of multiparticulate drug delivery system approach for high drug loading. AAPS PharmSciTech 18:2157–2167

    Article  CAS  PubMed  Google Scholar 

  • Silva A, Abrahim-Vieira B, Do Carmo F, Do Amaral L, Silva L et al (2014) Segregated delivery of rifampicin and isoniazid from fixed dose combination bilayer tablets for the treatment of tuberculosis. J Pharm Res Inter 4:1781–1801

    Google Scholar 

  • Singh S, Bhutani H, Mariappan T (2006) Quality problems of anti-tuberculosis fixed-dose combinations (FDCs): a way forward. Indian J Tuberc 53:201

    Google Scholar 

  • Spina D (2015) Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? Eur Clin Respir J 2:26634

    Article  Google Scholar 

  • Swapna B, Maddileti D, Nangia A (2014) Cocrystals of the tuberculosis drug isoniazid: polymorphism, isostructurality, and stability. Cryst Growth Des 14:5991–6005

    Article  CAS  Google Scholar 

  • Thakuria R, Sarma B (2018) Drug-drug and drug-nutraceutical cocrystal/salt as alternative medicine for combination therapy: a crystal engineering approach. Curr Comput Aided Drug Des 8:101

    Google Scholar 

  • Tiwari RV, Patil H, Repka MA (2016) Contribution of hot-melt extrusion technology to advance drug delivery in the 21st century. Expert Opin Drug Deliv 13:451–464

    Article  CAS  PubMed  Google Scholar 

  • Tobiska S, Kleinebudde P (2003) Coating uniformity and coating efficiency in a Bohle Lab-Coaterusing oval tablets. Eur J Pharm Biopharm 56:3–9

    Article  CAS  PubMed  Google Scholar 

  • Toschkoff G, Just S, Knop K, Kleinebudde P, Funke A et al (2015) Modeling of an active tablet coating process. J Pharm Sci 104:4082–4092

    Article  CAS  PubMed  Google Scholar 

  • Ugurlu T, Ozaydin T (2014) An overview on fixed dose combinations. Asian J Pharm Technol Innov 02(09):75–81

  • Us D, Chaudhari P, Bhavsar D, Chavan R (2013) Melt granulation: an alternative to traditional granulation techniques. Indian Drugs 50:03

    Google Scholar 

  • Valensi P, De Pouvourville G, Benard N, Chanut-Vogel C, Kempf C et al (2015) Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study. Diabetes Metab 41:231–238

    Article  CAS  PubMed  Google Scholar 

  • Van Kleef ME, Spiering W (2017) Hypertension: Overly important but under-controlled. Eur J Prev Cardiol 24:36–43

    Article  PubMed  Google Scholar 

  • Vasanthavada M, Wang Y, Haefele T, Lakshman JP, Mone M et al (2011) Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation. J Pharm Sci 100:1923–1934

    Article  CAS  PubMed  Google Scholar 

  • Vijayakumar TM, Jayram J, Cheekireddy VM, Himaja D, Teja YD et al (2017) Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res 84:4–9

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Vynckier A-K, Dierickx L, Saerens L, Voorspoels J, Gonnissen Y et al (2014a) Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core. Int J Pharm 464:65–74

    Article  CAS  PubMed  Google Scholar 

  • Vynckier AK, Dierickx L, Voorspoels J, Gonnissen Y, Remon JP et al (2014b) Hot-melt co-extrusion: requirements, challenges and opportunities for pharmaceutical applications. J Pharm Pharmacol 66:167–179

    Article  CAS  PubMed  Google Scholar 

  • Vynckier A-K, De Beer M, Monteyne T, Voorspoels J, De Beer T et al (2015) Enteric protection of naproxen in a fixed-dose combination product produced by hot-melt co-extrusion. Int J Pharm 491:243–249

    Article  CAS  PubMed  Google Scholar 

  • Vynckier AK, Voorspoels J, Remon JP, Vervaet C (2016) Co-extrusion as a processing technique to manufacture a dual sustained release fixed-dose combination product. J Pharm Pharmacol 68:721–727

    Article  CAS  PubMed  Google Scholar 

  • Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH et al (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32:3–15

    Article  CAS  PubMed  Google Scholar 

  • Wening K, Breitkreutz J (2010) Novel delivery device for monolithical solid oral dosage forms for personalized medicine. Int J Pharm 395:174–181

    Article  CAS  PubMed  Google Scholar 

  • Wening K, Breitkreutz J (2011) Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm 404:1–9

    Article  CAS  PubMed  Google Scholar 

  • Wilkins CA, Du Plessis LH, Viljoen JM (2020) Characterization of solid lipid dispersions prepared by hot fusion containing a double-fixed dose combination of artemether and lumefantrine. Drug Dev Ind Pharm 46:1289–1297

    Article  CAS  PubMed  Google Scholar 

  • Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J (2018) A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis 9:143

    Article  PubMed  PubMed Central  Google Scholar 

  • Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364:985–987

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization (1994) The promise and reality of fixed-dose combinations with rifampicin. Wkl Epidemiol Record Relev Épidémiol Hebd 69:219–220

  • World Health Organization WH (2005) Preparations DECOSFP. World Health Organization Geneva

  • World Health Organization (2011) WHO model list of essential medicines: 17th list 2011.

  • World Health Organization (2019) World Health Organization model list of essential medicines: 21st list 2019. World Health Organization

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Engineering, Cheongju University, Cheongju, 28530, Republic of Korea

    Dong-Wook Kim

  2. College of Pharmacy, Daegu Catholic University, Gyeongbuk, 38430, Republic of Korea

    Kwon Yeon Weon

Authors
  1. Dong-Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kwon Yeon Weon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kwon Yeon Weon.

Ethics declarations

Conflict of interest

All authors (D. W. Kim and K. Y. Weon) declare that they have no conflict of interest.

Statement of Human and Animal Rights

This article does not contain any studies with human and animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, DW., Weon, K.Y. Pharmaceutical application and development of fixed-dose combination: dosage form review. J. Pharm. Investig. 51, 555–570 (2021). https://doi.org/10.1007/s40005-021-00543-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-021-00543-x

Keywords

Search

Navigation